Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

ASCO® 2024 Summary: "Lymphoma Highlights"

2024 ASCO® Annual Meeting Insights Hub

B. D. Cheson

Has the 1L SoC Truly Changed in Advanced Stage DLBCL?

SOHO Brazil 2024

A. Zelenetz

R/R DLBCL: Are Bispecific Antibodies Superior to CAR-T?

Moffitt Cancer Center

J. Chavez

New Updates in Frontline DLBCL

Scripps Health

L. Nastoupil

Current Advances in the Treatment of Aggressive B- and T-Cell Lympho…

Indy Hematology Review

S. Smith

Top 5 Lymphoma Abstracts From ASH

Jennifer Amengual

Updates on Management of DLBCL

Louisville Hematology Highlights

J. Leonard

Sequencing of Bispecifics With Other Therapies in DLBCL

UChicago Medicine

E. Budde

Polatuzumab Vedotin for 1L DLBCL: Results From the POLARIX Trial

Wojciech Jurczak

How to Incorporate Bispecific Antibodies Into Your NHL Practice: A P…

Tara Graff

R/R DLBCL Case Discussion: 81 y/o Male Needing 3rd Line Treatment

Total Health

J. Chandler, B. Randolph, M. Onciu

ASCO® 2023 Insights: "Primary OS Analysis of the Phase 3 Randomized …

Insights from 2023 ASCO® Annual Meeting

J. Westin

Treatment Landscape in 1L DLBCL: Polatuzumab Vedotin as SoC

Georg Lenz

Current Management of DLBCL From Frontline to Relapsed Disease

Dipenkumar Modi

Tafasitamab + Lenalidomide vs. CIT for Transplant-Ineligible R/R DLB…

Patrizia Mondello

Practice-Changing Updates in DLBCL and HL

Massachusetts General Hospital Cancer Center

J. Erika Haydu

The Truth About Current Consensus Statements on Hematopoietic Cell T…

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

R. Gale

State of the Art and Next Questions: Aggressive B-Cell Lymphomas

SOHO Highlights: State of the Art and Next Questions

G. Nowakowski

ASCO® 2024 Summary: "Comparative Review of Toxicities and Their Mana…

2024 ASCO® Annual Meeting Insights Hub

M. Minnema